Board of Directors and Executive Management Team
Chief Executive Officer
Renzo is a proven, results-oriented Life Sciences senior executive with over 20 years of experience. His strong customer relationship management and business development skills has delivered significant growth through product deveolpment and strategic partnerships.
Renzo has extensive international experience working in North America, Europe, Asia and Africa. He has also inspired teams to innovate and deliver first-in world NDA approved therapeutic drugs and medical devices in a variety of cultures and languages (English, French and Italian).
Dr. Esmat Dessouki
Dr. Dessouki is a board certified Physician and President of ADA Medical Ltd. He is the Principal Investigator/Sub-investigator for more than 400 studies over 18 years. He has extensive experience with Neurology, Cardiology, Orthopaedics, Gastroenterology, Women’s Health, General Surgery, Endocrinology, Psychiatry, Urology, Oncology, Dermatology, Infectious, Disease, Internal Medicine, Ophthalmology, Otolaryngology and Nephrology.
Dr. Dessouki’s professional memberships include the Association of Clinical Research Professionals, The Royal College of Physicians and Surgeons of Canada, College of Physicians and Surgeons of Saskatchewan, Ontario Medical Association and Canadian Orthopaedic Association.
Dr. Fathi Abuzgaya
Chairman of the Board
Dr. Abuzgaya possesses over 17 years of clinical research experience, a board certified physician and the Chief Medical Officer of Ajax Hospital. He is also the CEO and Medical Director for ADA Medical. Dr. Abuzgaya has extensive experience with Neurology, Cardiology, Orthopaedics, Gastroenterology, Women’s Health, General Surgery, Endocrinology, Psychiatry, Urology, Oncology, Dermatology, Infectious Disease, Internal Medicine, Ophthalmology, Otolaryngology and Nephrology.
His professional memberships include the Canadian Medical Association, Ontario Medical Association, the Royal College of Physicians and Surgeons of Canada, The Royal College of Physicians and the Surgeons of Ontario.
Dr. Magdi Gaid
Member of the Board
Dr. Magdi Gaid is a certified Anesthesiolgist who graduated from medical school at Alexandria University and his post graduate training in London, U.K. and then at the University of Toronto. Dr. Gaid is currently a consultant at the Rouge Valley Heath System in Toronto, a board member of BioPharma Services, and sub-investigator in many studies done by BioPharma Services.
Dr. Gaid was also a sub-investigator for the first study in anesthesia induction medication done in Canada. He is a member of The Canadian Medical Association, Canadian Anesthesia Society, the College of Physicians, Surgeons of Ontario Canada and the Royal College of Physicians and Surgeons of Canada.
VP of Business Development
Lorelei is a graduate from the University of Toronto with a Bachelor of Science (Honors) degree specializing in human biology and nutritional sciences with an MBA degree from York University. Lorelei is the Secretary of the Canadian Society for Pharmaceutical Sciences (CSPS) and an active member of various associations such as AAPS and GPhA.
She is responsible for overall sales which include identifying and implementing all sales, marketing and external communication activities throughout North America, Europe and Asia.
Chief Financial Officer
Graduated as a Chartered Accountant with Institute of Chartered Accountants of Ontario and worked in a number of organizations both in the manufacturing and service industry with revenues up to $40 Million.
With over 20 years of experience managing and training staff in multi locations throughout North America, Wendy also implemented controls to reduce risk of fraud, set up accounting systems and streamlined them to meet the reporting needs of the board.
VP of Scientific Affairs
With a PhD and post-doctoral training in Physiology-Pharmacology at the Faculty of Pharmacy at the University of Montreal, Fethi has extensive experience in early clinical phase 1-2a drug development, including studies for PK/PD bioequivalence, Phase 1 SAD/MAD integrated design, Food effect, QTc, drug-drug interaction, Study in renal-impaired patients and Biosimilar development.
He is an expert in Hybrid generic/505(b)(2) programs for EU and USA NDA submissions from initial Pre-IND meetings up until the NDA submission to the agency and also well versed in Biosimilar early clinical development study design for PK/PD evaluation.